Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China

Table 5 Correlation of clinical parameters and achieving CR in the FL patients receiving R-based immunochemotherapy (n = 28)

Characteristic	Number	CR (n, %)	P
Age(years)			0.486
< 60	26	19 (73.1)
≥ 60	2	1 (50.0)
FLIPI			0.020
Low or medium risk (≤2)	22	18 (81.8)
High risk (≥3)	6	2 (33.3)
Bone marrow involvement
Yes	19	12 (63.2)	0.159
no	9	8 (88.9)
β2-MG (mg/L)			0.967
< 3.5	17	12 (70.6)
≥ 3.5	7	5 (71.4)
LDH (U/L)			0.334
< 220	21	16 (76.2)
≥ 220	7	4 (57.1)

ISSN: 1471-2407